Acarix AB (publ) (ACIXF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acarix AB (publ) (ACIXF). Acarix AB (publ) is a Swedish medical device company specializing in AI-based solutions for coronary artery disease (CAD) rule-out. Its CADScor System utilizes acoustics and AI to analyze coronary blood flow at the point of care. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Acarix AB (publ) (ACIXF) Healthcare & Pipeline Overview
Acarix AB (publ) develops and commercializes the CADScor System, a point-of-care diagnostic tool using AI and acoustics for rapid coronary artery disease rule-out. Operating in the medical specialties sector, the company aims to improve diagnostic efficiency and patient outcomes in Sweden and internationally.
Investment Thesis
Acarix AB (publ) presents a focused investment opportunity within the medical device sector, centered on its CADScor System for rapid CAD rule-out. The company's high gross margin of 73.0% indicates strong pricing power and potential for profitability as sales scale. Key value drivers include expanding market adoption of the CADScor System in both Sweden and international markets. Growth catalysts involve securing regulatory approvals in new geographies and demonstrating clinical and economic benefits to healthcare providers. However, the company's negative P/E ratio of -7.05 and a negative profit margin of -653.4% highlight the risks associated with its current financial performance and reliance on future revenue growth. The company's small market capitalization of $0.03 billion also introduces liquidity and volatility considerations for investors.
Based on FMP financials and quantitative analysis
Key Highlights
- CADScor System offers a non-invasive method for CAD rule-out, potentially reducing the need for more invasive procedures.
- Gross margin of 73.0% indicates strong pricing power.
- Focus on AI-based diagnostics positions the company in a growing area of medical technology.
- Small team of 8 employees allows for agile operations but also presents scalability challenges.
- Geographic focus on Sweden and international markets provides growth opportunities but also exposes the company to regulatory and market-specific risks.
Competitors & Peers
Strengths
- Innovative AI-based diagnostic technology.
- Non-invasive and rapid CAD rule-out.
- High gross margin.
- Potential for cost savings in healthcare systems.
Weaknesses
- Small company with limited resources.
- Negative profitability.
- Dependence on a single product.
- Limited market presence outside of Sweden.
Catalysts
- Ongoing: Market penetration and adoption of the CADScor System in existing markets.
- Upcoming: Potential regulatory approvals in new geographic regions.
- Upcoming: Publication of clinical studies demonstrating the efficacy and cost-effectiveness of the CADScor System.
- Ongoing: Development and launch of new AI-powered diagnostic tools.
- Ongoing: Strategic partnerships with healthcare providers and telehealth platforms.
Risks
- Potential: Competition from established medical device companies with greater resources.
- Potential: Regulatory hurdles and reimbursement challenges in new markets.
- Ongoing: Dependence on a single product (CADScor System).
- Potential: Technological obsolescence and the emergence of competing diagnostic technologies.
- Ongoing: Limited financial resources and the need for additional funding.
Growth Opportunities
- Expansion into new geographic markets: Acarix has the opportunity to expand its market presence beyond Sweden and target other European countries, North America, and Asia. Securing regulatory approvals and establishing distribution partnerships in these regions could significantly increase sales of the CADScor System. The global market for cardiovascular diagnostic devices is projected to reach billions of dollars, offering a substantial growth runway for Acarix over the next 3-5 years.
- Increased adoption in primary care settings: The CADScor System's ease of use and rapid results make it well-suited for primary care settings. By targeting primary care physicians, Acarix can increase the adoption of its technology as a first-line diagnostic tool for patients presenting with chest pain or other symptoms suggestive of CAD. This could lead to earlier detection and management of the disease, improving patient outcomes and reducing the burden on specialist cardiology services. Timeline for adoption is 2-3 years.
- Development of new AI-powered diagnostic tools: Acarix can leverage its expertise in acoustics and artificial intelligence to develop new diagnostic tools for other cardiovascular conditions or related diseases. This could involve expanding the capabilities of the CADScor System or creating entirely new products that address unmet needs in the market. Investing in research and development to broaden its product portfolio could drive long-term growth and diversification. Expect new products in 3-5 years.
- Strategic partnerships with healthcare providers: Collaborating with hospitals, clinics, and integrated delivery networks can provide Acarix with access to a larger patient base and streamline the adoption of the CADScor System. These partnerships could involve pilot programs, clinical studies, and bundled service offerings that demonstrate the value of the technology. Building strong relationships with key healthcare stakeholders is crucial for driving market penetration and establishing Acarix as a trusted provider of diagnostic solutions. Partnerships can be expected within the next 1-2 years.
- Integration with telehealth platforms: As telehealth becomes increasingly prevalent, Acarix can integrate its CADScor System with telehealth platforms to enable remote monitoring and diagnosis of patients at risk of CAD. This could involve developing a home-based version of the device or partnering with telehealth providers to offer remote diagnostic services. Integrating with telehealth could expand the reach of the CADScor System and improve access to care for patients in remote or underserved areas. Integration can be expected in the next 2-3 years.
Opportunities
- Expansion into new geographic markets.
- Increased adoption in primary care settings.
- Development of new AI-powered diagnostic tools.
- Strategic partnerships with healthcare providers.
Threats
- Competition from established medical device companies.
- Regulatory hurdles and reimbursement challenges.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Proprietary AI algorithms for analyzing coronary blood flow.
- Patented acoustic sensor technology.
- First-mover advantage in the market for AI-based CAD rule-out.
- Established relationships with healthcare providers in Sweden.
About ACIXF
Founded in 2009 and headquartered in Malmö, Sweden, Acarix AB (publ) is a medical device company focused on improving the diagnosis of coronary artery disease (CAD). The company's core product is the CADScor System, a non-invasive, point-of-care diagnostic aid that utilizes sensitive acoustics and advanced artificial intelligence to analyze a patient's coronary blood flow. This system is designed to provide a rapid rule-out of CAD, potentially reducing the need for more invasive and costly diagnostic procedures. The CADScor System aims to offer a more efficient and accessible method for identifying patients at low risk of CAD, thereby streamlining the diagnostic pathway. Acarix targets healthcare providers in Sweden and other international markets, offering a solution that can be integrated into primary care and cardiology settings. The company's focus is on leveraging technology to improve patient outcomes and reduce healthcare costs associated with CAD diagnosis. With a small team of 8 employees, Acarix operates with a focus on innovation and market expansion within the medical device industry.
What They Do
- Develops the CADScor System, a point-of-care diagnostic aid for coronary artery disease (CAD).
- Utilizes sensitive acoustics to analyze a patient's coronary blood flow.
- Employs advanced artificial intelligence (AI) to interpret acoustic data.
- Provides a rapid rule-out of CAD, potentially reducing the need for invasive procedures.
- Targets healthcare providers in Sweden and internationally.
- Offers a non-invasive method for assessing CAD risk.
- Aims to improve diagnostic efficiency and patient outcomes.
Business Model
- Sells the CADScor System to hospitals, clinics, and other healthcare providers.
- Generates revenue from the sale of disposable sensors used with the CADScor System.
- May offer service and maintenance contracts for the CADScor System.
- Potentially generates revenue from data analysis and reporting services.
Industry Context
Acarix AB (publ) operates within the medical device industry, specifically in the market for cardiovascular diagnostics. The industry is characterized by technological innovation, increasing demand for non-invasive diagnostic methods, and a growing prevalence of cardiovascular diseases. The competitive landscape includes established medical device companies and emerging players offering various diagnostic solutions. Acarix aims to differentiate itself through its AI-powered CADScor System, focusing on rapid and cost-effective CAD rule-out at the point of care. The market is driven by the need for efficient and accurate diagnostic tools to improve patient outcomes and reduce healthcare costs.
Key Customers
- Cardiologists and cardiology clinics
- Primary care physicians and general practitioners
- Hospitals and emergency departments
- Healthcare systems and integrated delivery networks
Financials
Chart & Info
Acarix AB (publ) (ACIXF) stock price: Price data unavailable
Latest News
No recent news available for ACIXF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACIXF.
Price Targets
Wall Street price target analysis for ACIXF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ACIXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Aamir Mahmood
CEO
Aamir Mahmood is the CEO of Acarix AB (publ). Information regarding his detailed background, career history, education, and previous roles is not available in the provided data. As the CEO, he is responsible for leading the company's strategic direction, overseeing operations, and driving growth in the market for AI-based coronary artery disease diagnostics.
Track Record: Due to the limited information available, Aamir Mahmood's specific achievements, strategic decisions, and company milestones under his leadership cannot be detailed. His role involves guiding the company through its development and commercialization efforts for the CADScor System.
ACIXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acarix AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as exchange-listed companies. Investing in OTC Other stocks carries a higher degree of risk due to the potential for limited information, price volatility, and illiquidity compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Potential for low trading volume and illiquidity.
- Higher price volatility compared to exchange-listed stocks.
- Risk of inadequate regulatory oversight.
- Potential for fraud or misrepresentation due to limited scrutiny.
- Verify the company's registration and legal status.
- Assess the company's financial statements (if available).
- Research the background and experience of the company's management team.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Company has a functional website and contact information.
- Company has been in operation for several years (founded in 2009).
- Company has a patent for its CADScor System.
- Company has partnerships with healthcare providers (if any are publicly known).
- Company has a CEO and management team.
What Investors Ask About Acarix AB (publ) (ACIXF)
What does Acarix AB (publ) do?
Acarix AB (publ) is a medical device company that develops and commercializes the CADScor System, a non-invasive diagnostic tool for coronary artery disease (CAD). The CADScor System utilizes sensitive acoustics and advanced artificial intelligence to analyze a patient's coronary blood flow at the point of care. This technology aims to provide a rapid rule-out of CAD, potentially reducing the need for more invasive and costly diagnostic procedures. Acarix targets healthcare providers in Sweden and internationally, offering a solution that can be integrated into primary care and cardiology settings.
What do analysts say about ACIXF stock?
AI analysis is currently pending for ACIXF. Without analyst consensus or ratings, valuation metrics are limited to the available financial data. The company's negative P/E ratio and profit margin reflect its current stage of development and reliance on future growth. Investors should conduct their own thorough due diligence and consider the risks and opportunities associated with this stock.
What are the main risks for ACIXF?
The main risks for Acarix AB (publ) include its small size and limited financial resources, which could hinder its ability to compete with larger, more established medical device companies. The company's dependence on a single product (CADScor System) also poses a risk, as does the potential for technological obsolescence. Regulatory hurdles and reimbursement challenges in new markets could also impede its growth. Additionally, the company's OTC Other tier status introduces liquidity and transparency risks.
What are the key factors to evaluate for ACIXF?
Evaluating ACIXF involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Innovative AI-based diagnostic technology.. Primary risk to monitor: Potential: Competition from established medical device companies with greater resources.. This is not financial advice.
How frequently does ACIXF data refresh on this page?
ACIXF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ACIXF's recent stock price performance?
Recent price movement in Acarix AB (publ) (ACIXF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative AI-based diagnostic technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ACIXF overvalued or undervalued right now?
Determining whether Acarix AB (publ) (ACIXF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ACIXF?
Before investing in Acarix AB (publ) (ACIXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for certain sections, particularly regarding CEO background and analyst opinions.
- OTC market data may be less reliable than exchange-listed data.